CAPSOVISION INC

CapsoVision reported Q2 revenue of $3.6 million (+10%) and an adjusted EPS of -$0.15, missing the consensus of -$0.11. Gross margin fell to 51% and operating expenses rose 46% to $9.5 million, pressured by development costs, tariffs and price competition. Management expects a stronger second half, plans a US launch of "AI Highlights" after expected FDA approval and has an ATM program of up to $100 million available; the stock dropped sharply after hours. » Más en de.investing.com

CapsoVision has announced the international launch of AI Highlights for the CapsoCam Plus system. The AI analyzes capsule endoscopy recordings during video processing, flags images suspected of clinically relevant findings, and is integrated into the CapsoView software and the CapsoCloud platform. The feature is available in markets where CapsoView/CapsoCloud are regulatory approved, including the EU; in the US, AI Highlights is not FDA‑approved and is not commercially available. The application is intended for trained medical professionals and does not replace clinical judgment. » Más en de.investing.com